Dissecting the immune landscape in pediatric high-grade glioma reveals cell state changes under therapeutic pressure

Pediatric high-grade gliomas (pHGGs) are among the most lethal childhood tumors. While therapeutic approaches were largely adapted from adult treatment regime, significant biological differences between pediatric and adult gliomas exist, which influence the immune microenvironment and may contribute to the limited response to current pHGG treatment strategies. We provide a comprehensive transcriptomic analysis of the pHGG immune landscape using single-cell RNA sequencing and spatial transcriptomics. We analyze matched malignant, myeloid, and T cells from patients with pediatric diffuse high-grade glioma (HGG) or high-grade ependymoma, examining immune microenvironment distinctions after chemo-/radiotherapy, immune checkpoint inhibition treatment, and by age. Our analysis reveals differences in the proportions of pediatric myeloid subpopulations compared to adult counterparts. Additionally, we observe significant shifts toward immune-suppressive environments following cancer therapy. Our findings offer valuable insights into potential immunotherapy targets and serve as a robust resource for understanding immune microenvironmental variations across HGG age groups and treatment regimens.

Authors

Institutions

Publication Details

Journal
Cell Reports Medicine
Published
2025-05-01
DOI
https://doi.org/10.1016/j.xcrm.2025.102095
Citations
5
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
8.13

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Dissecting the immune landscape in pediatric high-grade glioma reveals cell state changes under therapeutic pressure

Sanda Alexandrescu, Keith L. Ligon, Robert Michael Prins, Ilon Liu et al.
5 citations
Cell Reports Medicine
Glioma Diagnosis and Treatment
8.13
article

Dissecting the immune landscape in pediatric high-grade glioma reveals cell state changes under therapeutic pressure

Sanda Alexandrescu, Keith L. Ligon, Robert Michael Prins, Ilon Liu, René Geyeregger, Tom B. Davidson, McKenzie Shaw, Gustavo Alencastro Veiga Cruzeiro, Irene Slavc, Maria Trissal, Orr Ashenberg, Sibylle Madlener, Kai W. Wucherpfennig, Nathan D. Mathewson, Johannes Gojo, Alexander Beck, Natalia Stepien, Daniela Loetsch, Anže Godicelj, Jenna LaBelle, Sascha Marx, Alicia Baumgartner, Bernhard Englinger, Carlos Alberto Oliveira de Biagi, Hart G.W. Lidov, Olivia A. Hack, Andrezza Nascimento, Christian Dorfer, Tom Rosenberg, Jayne Vogelzang, Jacob S Rozowsky, Lissa Baird, Kee Kiat Yeo, Tabitha Cooney, Jason W. Pyrdol, Da-Eun Jeong, Sina Neyazi, Christine Haberler, Andreas Peyrl, Lisa Mayr, Jacob Haase, Jiang Li, Cuong Nguyen, Sophia Castellani, Rebecca D Haase, Adrienne M Luomo
article en
5 citations

Abstract

Pediatric high-grade gliomas (pHGGs) are among the most lethal childhood tumors. While therapeutic approaches were largely adapted from adult treatment regime, significant biological differences between pediatric and adult gliomas exist, which influence the immune microenvironment and may contribute to the limited response to current pHGG treatment strategies. We provide a comprehensive transcriptomic analysis of the pHGG immune landscape using single-cell RNA sequencing and spatial transcriptomics. We analyze matched malignant, myeloid, and T cells from patients with pediatric diffuse high-grade glioma (HGG) or high-grade ependymoma, examining immune microenvironment distinctions after chemo-/radiotherapy, immune checkpoint inhibition treatment, and by age. Our analysis reveals differences in the proportions of pediatric myeloid subpopulations compared to adult counterparts. Additionally, we observe significant shifts toward immune-suppressive environments following cancer therapy. Our findings offer valuable insights into potential immunotherapy targets and serve as a robust resource for understanding immune microenvironmental variations across HGG age groups and treatment regimens.

Cell Reports MedicineVol. 6(5)
Broad Institute (US), Brigham and Women's Hospital (US), Boston Children's Hospital (US), Children's Hospital of Los Angeles (US), Harvard University (US), Heidelberg University (DE), Humboldt-Universität zu Berlin (DE), Comprehensive Cancer Center Vienna (AT), Parker Institute for Cancer Immunotherapy (US), Hopp Children's Cancer Center Heidelberg (DE), Dana-Farber Cancer Institute (US), Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE), Dana-Farber Brigham Cancer Center (US), Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US), Medical University of Vienna (AT), Ludwig-Maximilians-Universität München (DE)
National Cancer Institute
Good health and well-being
Openalex Percentile: Top 3%
Glioma Diagnosis and Treatment
8.13
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.